AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY"

Transcription

1 AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY

2 THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes in formalin-fixed, paraffin-embedded (FFPE) tissue specimens. 1 Produces direct quantitative measurement of HER2 protein, the target of current anti-her2 drug therapies. 2 Provides a continuous, rather than semiquantitative, measurement of HER2 total protein over a 3-log dynamic range. 2 Demonstrates a 7-to-10 fold improvement in sensitivity over IHC, with detection of HER2 levels down to ~2,500 receptors per cell. 2 Clinical Significance of HERmark HERmark Provides Accurate HER2 Assessment and Prognostic Value Accurate assessment of HER2 status in breast cancer is critical in identifying patients who may benefit from HER2-targeted therapy. Studies have shown that there still is a relatively high discordance level (18-27%) between central and local HER2 testing. 3,4 Representing real-world HER2 testing, a recent retrospective, multicenter Collaborative Biomarker Study (CBS) of breast cancer patients (not treated with trastuzumab) showed that the HERmark assay offers accurate quantification of HER2 protein expression that correlated best with central laboratory HER2 IHC re-testing, and less so with local laboratory HER2 IHC and FISH results: 5 HERmark reclassified 15% of local HER2 status negative results as HERmark positives. HERmark offers a more accurate assessment of HER2 status and may change therapy selection in approximately 20% of patients. HERmark has shown to be a better prognostic factor in overall survival in patients for whom HER2 test results were discordant between HERmark and routine HER2 testing. The difference in overall survival with the discordant groups did not appear to be due to clinicopathologic factors but more likely due to local HER2 misclassifications. A Quantitative H2T Levels A. Discordant High 9% A. Discordant High 9% 10% 10% B Overall Survival (%) A. Discordant High Concordant Nega ve Concordant Nega ve A. Concordant Discordant Posi ve High Concordant Posi ve Local HER2 negative Local HER2 positive Time Since Diagnosis (months) Adapted from Yardley et al., Breast Cancer Research 2015; 17:41 5 Figure A. HER2 status as stratified by local HER2 status and HERmark levels. HERmark may offer a more accurate assessment of HER2 status when compared to local HER2 measurements, and may change therapy selection in approximately 20% of patients (A. and B.). Figure B. Kaplan-Meier overall survival analyses for corresponding HERmark concordant and discordant groups. HERmark High (A. Discordant High) and HERmark Low () had similar overall survival curves compared to concordant HERmark/local HER2 positive and concordant HERmark/local HER2 negative, respectively.

3 Better Correlation with Clinical Outcomes on Trastuzumab 6 Our HERmark clinical study showed HERmark outperformed FISH as a predictor of time to progression (TTP) in patients with metastatic breast cancer treated with trastuzumab (n=102). 2.5 EXAMINATION OF HERMARK/FISH DISCORDANCE 100 TIME TO PROGRESSION (TTP) 2.0 CONCORDANT POSITIVE FISH(+), HER2 Total high HERmark HER2 Total high, FISH(+): Median TTP = 11.3 months Hazard Ratio (HR) compared to: HERmark HER2 Total low, FISH(+) = 0.43, P = 0.01 HERmark HER2 Total low, FISH( ) = 0.42, P < Log 10 HER2 Total Negative H2T CUTOFF LOG(H2T) = 1.14 CONCORDANT NEGATIVE FISH( ), HER2 Total low FISH DISCORDANT FISH(+), HER2 Total low Positive Percent Progression Free HERmark HER2 Total low, FISH(+): Median TTP = 3.7 months HERmark HER2 Total low, FISH( ): Median TTP = 4.5 months Time (Months) Patients with HER2 FISH-positive (HER2/CEP17 ratio 2.2) samples that were reclassified by HERmark as HER2-low (H2T low) had similar TTP as patients with FISH-negative results (3.7 months and 4.5 months, respectively) (HR, 1.0; p=0.99). HERmark Provides Predictive Value HERmark measurements were performed in tumors of patients (n=324) enrolled in the NeoALTTO trial. The NeoALTTO trial evaluated neoadjuvant treatment of lapatinib with trastuzumab vs. either treatment alone for HER2-positive early stage breast cancer. The results of this study include: HERmark results were predictive of pathologic complete response (pcr) when patients received trastuzumab or trastuzumab in combination with lapatinib. 7 HERmark positive patients had better outcomes and achieved a pcr rate of 39% vs. 11% for HERmark negative (plus equivocal). 8 Higher HERmark values achieved better outcomes in the combination arm (lapatinib and trastuzumab) compared to trastuzumab alone. 7 Higher HERmark value=increased benefit from addition of lapatinib to trastuzumab Lower HERmark (but still HER2 positive by IHC/FISH)=reduced benefit from combination treatment Predicted probability of pcr HERmark-negative Eq. HERmark-positive HER2 levels (all patients) Addition of lapatinib to tastuzumab Large benefit Reduced benefit

4 Better Correlation with Time to Brain Metastasis 9 HERmark HER2 protein levels correlated with risk of brain metastases in HER2-positive metastatic breast cancer patients receiving trastuzumab therapy. Time to brain metastases by A.) HERmark (H2T) median cutoff or B.) FISH/CEP17 ratio median cutoff within the HER2 FISH-positive group of patients A B HR, 2.4; p=0.005 HR, 1.3; p=0.4 Comparison with Other HER2 Testing Methods In validation studies involving more than 1,000 clinical tumor samples, HERmark demonstrated a high level of concordance* with other HER2 testing methods performed in central reference laboratories. Central IHC 10,11 n=808 Central FISH 12 n=116 Central IHC and CISH 10 n=218 HERmark Assay 96-98% 93% 97% *Note: Concordance values exclude equivocal results 13 HERmark results are reported as Patient HER2 Status (positive, negative, or equivocal) as well as the patient s precise quantitative HER2 level. The HER2 level is compared to a database with established HERmark reference ranges (1,090 breast cancer patient samples previously defined as HER2-positive or negative according to central reference lab IHC and FISH/CISH). When to Use HERmark HERmark offers an alternative HER2 testing method in order to identify candidates for HER2-targeted therapy. Consider HERmark: When a fully quantitative and validated HER2 protein measurement is desired. When HER2 status is inconclusive: Cases with discordant HER2 testing results in IHC and/or FISH (CISH) Cases with HER2 status equivocal by IHC and/or FISH (CISH) Cases that demonstrate significant heterogeneity in the expression of HER2 protein or gene amplification status of HER2 In cases with HER2 status negative by IHC and/or ISH (FISH/CISH), but the patient s clinical picture (by physician s assessment and experience) suggests an aggressive (possibly HER2-positive) disease.

5 HERmark Assay Methodology 1 The HERmark assay specifically quantifies the full range of HER2 protein expression (H2T) levels in FFPE breast cancer tumor samples. The VeraTag methodology uses two primary HER2-specific monoclonal antibodies and proximity-based conjugated fluorescent VeraTag reporters that are quantified using capillary electrophoresis. The amount of released VeraTag reporters is proportional to the amount of HER2 protein in the invasive tumor sample. HERmark breast cancer assay based on VeraTag technology Novel proximitybased method Direct, quantitative measure of the drug target, HER2 protein HERmark breast cancer assay based FISH, CISH, on SISH, VeraTag and microarrays technology are indirect assays of protein expression Direct, Dual antibody quantitative format measure enhances specificity, of the drug target, HER2 protein minimizes background, and FISH, results CISH, in SISH, greater and signal/noise microarrays ratio are indirect assays of protein expression Dual antibody format enhances specificity, minimizes background, and results in greater signal/noise ratio 2 References 1. Shi, Y, Huang, W, Tan, Y, et al. A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue. Diagn Mol Pathol 2009; 18(1): Larson, JS, Goodman, LJ, Tan, Y, et al., Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark ) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens. Patholog Res Int. 2010; 2010: Paik, S et al., Real-World Performance of HER2 Testing National Surgical Adjuvant Breast and Bowel Project Experience. J Natl Cancer Inst 2002; 94: Denkert, C et al., HER2 and ESR1 mrna expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer. Breast Cancer Research 2013; 15:R Yardley, DA et al., Quantitative measurement of HER2 expression in breast cancers: comparison with real-world routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival. Breast Cancer Research 2015; 17: Lipton, A, Köstler, W, Leitzel, K, et al., Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 2010;116:(22): Scaltriti, M et al., High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clin Cancer Res 2015; 2193): Scaltriti, M et al., High HER2 Expression Correlates with Response to Trastuzumab and the Combination of Trastuzumab and Lapatinib in the NeoALTTO Phase III Trial. Cancer Res 2013; 73(24 Suppl):Abstract nr P Duchnowska, R, Biernat, W, Szostakiewicz, B, et al., Correlation Between Quantitative HER-2 Protein Expression and Risk for Brain Metastases in HER-2+ Advanced Breast Cancer Patients Receiving Trastuzumab-Containing Therapy. The Oncologist 2012; 17(1): Joensuu, H, Weidler, J, Lie, Y, et al., Quantitative measurements of HER2 expression and HER2 homodimers using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study. San Antonio Breast Cancer Symposium, Abstract # Huang, W, Reinholz, M, Weidler J, et al., Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity based assay. Am J Clin Pathol 2010;134: Duchnowska, R, Szostakiewicz, B, Jankowski, T, et al., Correlation between quantitative HER2 protein level and the risk of brain metastasis (BM) in metastatic breast cancer (MBC) patients (pts) treated with trastuzumab-containing therapy. ASCO Annual Meeting J Clin Oncol 28:15s, 2010 (suppl; abstr 1030). 13. Wolff, AC, Hammond, ME, Schwartz, JN, et al., American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol 2006; 25:

6 Specimen Requirement Options Unstained slides 5-μm sections on positively-charged glass slides, 1 section per slide. A total of 5 unstained slides per patient is required (sections should contain 10 mm 2 invasive tumor). Freshly cut sections, stored at 4 C, and sent within 1 week. OR 1 paraffin-embedded tissue block (requires formalin-fixed tissue) If multiple blocks are available, select the tissue block with the highest amount of viable invasive tumor submit only 1 block. Note: Invasive carcinoma of the breast is required; cases with in situ disease only (e.g., DCIS or LCIS) are not acceptable. Fine needle aspiration (FNA) specimens are not acceptable. Excisional biopsy specimens are preferred; large core biopsies are also acceptable. Reimbursement Assistance Gateway Services can assist your office and your patients with obtaining coverage and reimbursement for HERmark. Gateway makes reimbursement assistance as easy as 1-2-3: Call Gateway at prior to ordering a HERmark assay. The appropriate application forms will be sent to you via fax or . Complete the application forms and return them to Gateway via fax, Receive notification from Gateway of patient eligibility, typically within 24 to 48 hours. In the event that verification/coverage cannot be established, Gateway can assist with the patient s case and/or research alternative coverage Laboratory Corporation of America Holdings. All rights reserved. onc-488-v L

Name of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Name of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers Name of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers Policy #: 487 Latest Review Date: January 2016 Category: Laboratory Policy Grade: B Background/Definitions:

More information

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers

Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Quantitative Assay for Measurement of HER2 Total Protein Expression

More information

HER2 Testing in Breast Cancer

HER2 Testing in Breast Cancer HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor

More information

ASCO CAP HER2 Test Guideline Recommendations Summary of Guideline 2007 and 2013 Recommendations

ASCO CAP HER2 Test Guideline Recommendations Summary of Guideline 2007 and 2013 Recommendations ASCO CAP HER2 Test Guideline Recommendations Summary of Guideline 2007 and 2013 Recommendations Topic 2007 Recommendation 2013 Recommendation Specimens to be tested algorithm for HER2 testing All primary

More information

PATHOLOGY. HercepTestTM. Product Information

PATHOLOGY. HercepTestTM. Product Information PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying

More information

MEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14

MEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14 MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,

More information

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns

Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

Measurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center

Measurement of HER2. Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Measurement of HER2 Daniel F. Hayes, MD Clinical Director, Breast Oncology Program University of Michigan Comprehensive Cancer Center Trastuzumab Metastatic Adjuvant Lapatinib Metastatic Trials Why Test

More information

Complimentary CME. Metastatic Breast Cancer: Monitoring Soluble HER2 Levels

Complimentary CME. Metastatic Breast Cancer: Monitoring Soluble HER2 Levels Complimentary CME Metastatic Breast Cancer: Monitoring Soluble HER2 Levels Program Description HER2/neu-positive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis.

More information

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015 Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer

More information

HER2 FISH pharmdx. Assay Kit

HER2 FISH pharmdx. Assay Kit PATHOLOGY HER2 FISH pharmdx Assay Kit HER2 FISH pharmdx Clarity You Can Count On Reliable Results at a Glance The robust HER2 FISH pharmdx assay offers bright and distinct signals for easy and fast reading

More information

Miquel Àngel Seguí Palmer

Miquel Àngel Seguí Palmer Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with

More information

ASCO-CAP Guidelines for Breast Predictive Factor Testing

ASCO-CAP Guidelines for Breast Predictive Factor Testing ASCO-CAP Guidelines for Breast Predictive Factor Testing M. Elizabeth Hammond MD Pathologist, Intermountain Healthcare Professor of Pathology, University of Utah School of Medicine Agenda Why ASCO-CAP

More information

Understanding Your Breast Cancer Pathology Report *

Understanding Your Breast Cancer Pathology Report * Understanding Your Breast Cancer Pathology Report * * Note: Your pathology report may contain all or some of the sections covered in this guide. Remember, your healthcare team is always available to help

More information

Monitoring Soluble HER2 Levels in Patients with Metastatic Breast Cancer

Monitoring Soluble HER2 Levels in Patients with Metastatic Breast Cancer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

HER2 TESTING IN BREAST CANCER Clinical Practice Guideline Update

HER2 TESTING IN BREAST CANCER Clinical Practice Guideline Update HER2 TESTING IN BREAST CANCER Clinical Practice Guideline Update American Society of Clinical Oncology / College of American Pathologists Introduction & Context Original joint ASCO/CAP HER2 Testing Guideline

More information

I. THE IMPORTANCE OF HER2 IN BREAST CANCER

I. THE IMPORTANCE OF HER2 IN BREAST CANCER I. THE IMPORTANCE OF HER2 IN BREAST CANCER The human epidermal growth factor receptors (HER), also known as ERBB receptors, are a family of signal transduction proteins. There are 4 family members in humans

More information

HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges

HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges Technical Articles HER2 Testing in Gastric and Esophageal Adenocarcinoma: Emerging Therapeutic Options and Diagnostic Challenges Christa L. Whitney-Miller, MD David G. Hicks, MD Department of Pathology

More information

BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy

BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Adjuvant treatment of breast cancer patients with trastuzumab

Adjuvant treatment of breast cancer patients with trastuzumab doi:10.2478/v10019-007-0020-y review Adjuvant treatment of breast cancer patients with trastuzumab Erika Matos, Tanja Čufer Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a

More information

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management

A Gene Expression Test to Predict Prostate Cancer Aggressiveness. Use Prolaris as a guide in your medical and surgical management A Gene Expression Test to Predict Prostate Cancer Aggressiveness Use Prolaris as a guide in your medical and surgical management What is Prolaris? A direct molecular measure of prostate cancer tumor biology

More information

Published Ahead of Print on August 9, 2016 as 10.1200/JCO.2015.61.8983. J Clin Oncol 34. 2016 by American Society of Clinical Oncology INTRODUCTION

Published Ahead of Print on August 9, 2016 as 10.1200/JCO.2015.61.8983. J Clin Oncol 34. 2016 by American Society of Clinical Oncology INTRODUCTION Published Ahead of Print on August 9, 2016 as 10.1200/JCO.2015.61.8983 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2015.61.8983 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E

More information

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?

What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival

More information

Laboratory Testing for Her2 Status in Breast Cancer

Laboratory Testing for Her2 Status in Breast Cancer Laboratory Testing for Her2 Status in Breast Cancer Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology May 28, 2015 Overview Clinical relevance of Her2 status for treatment of breast

More information

The HER2 oncogene encodes a

The HER2 oncogene encodes a Ask the Experts HER2 Testing in Gastric/Gastro-Esophageal Junction Adenocarcinomas and Breast Cancer: Similarities and Differences Jeffrey S. Ross, MD Department of athology and Laboratory Medicine Albany

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

The Oncotype DX Breast Cancer Assay helps you find an answer

The Oncotype DX Breast Cancer Assay helps you find an answer CHEMO? NO CHEMO? The Oncotype DX Breast Cancer Assay helps you find an answer Oncotype DX helps clarify one of the most difficult treatment questions by providing an individualized Recurrence Score result

More information

Understanding your pathology report

Understanding your pathology report Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What

More information

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I

BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness

More information

How Much IS Too Much? Who Needs Adjuvant Chemotherapy?

How Much IS Too Much? Who Needs Adjuvant Chemotherapy? How Much IS Too Much? Who Needs Adjuvant Chemotherapy? Deena Damsky Dell RN, MSN, AOCN,BC Clinical Nurse Specialist Fox Chase Cancer Center Philadelphia, PA What We Know: Survival Is Improved.But We treat

More information

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

More information

HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays

HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays O R I G I N A L A R T I C L E HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays TK Yau H Sze Inda S Soong F Hioe

More information

HER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic Breast Cancer. Ann Thor M.D.

HER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic Breast Cancer. Ann Thor M.D. PSC/USCAP 2008 Applications of Molecular Analysis to Small Biopsy and Cytology Specimens for Diagnosis and Targeted Therapy HER2/neu (erbb2) Analysis on FNA Smears and Core Biopsies of Primary or Metastatic

More information

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10

Issued: September 2013. NICE diagnostics guidance 10. www.nice.org.uk/dg10 Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September

More information

Roadmap. Why Test for HER2? How do we test for HER2? Bright-field ISH. How do we test for HER2?

Roadmap. Why Test for HER2? How do we test for HER2? Bright-field ISH. How do we test for HER2? Roadmap Challenges in Breast Cancer Predictive Marker Interpretation Kimberly H Allison, MD Associate Profess of Pathology Specialist in Breast Pathology Stanfd University Medical Center allisonk@stanfd.edu

More information

Appendix One. HER2-positive early breast cancer, its treatment and prognosis

Appendix One. HER2-positive early breast cancer, its treatment and prognosis Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf

More information

Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?

Receptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary? Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000

More information

TESTING FOR HER2 POSITIVE BREAST CANCER: A COST- EFFECTIVENESS ANALYSIS

TESTING FOR HER2 POSITIVE BREAST CANCER: A COST- EFFECTIVENESS ANALYSIS FINAL Report No 23 TESTING FOR HER2 POSITIVE BREAST CANCER: A COST- EFFECTIVENESS ANALYSIS Report available at www.mcgill.ca/tau/ May 15 th 2006 1 This report was prepared for the Technology Assessment

More information

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith,

March 19, 2014. Dear Dr. Duvall, Dr. Hambrick, and Ms. Smith, Dr. Daniel Duvall, Medical Officer Center for Medicare, Hospital and Ambulatory Policy Group Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244 Dr. Edith Hambrick,

More information

Tissue Biomarkers in Oncology Clinical Development The Digital Advantage

Tissue Biomarkers in Oncology Clinical Development The Digital Advantage Tissue Biomarkers in Oncology Clinical Development The Digital Advantage Christopher Ung VP Strategic Business & Operations, Oncology TMD A Quintiles Laboratory 1 The Targeted Therapy Continuum Non-Targeted

More information

Since the approval of trastuzumab

Since the approval of trastuzumab Diagnostics HER2 Diagnostics in Gastric Cancer Oliver Stoss, PhD, Martina Schmitt, PhD, Dirk Zielinski, PhD, Thomas Henkel, PhD Iris Nagelmeier, MD Josef Rüschoff, MD Targos Molecular Pathology Germaniastrasse

More information

Theories on Metastasis: Innovative Thinking An Advocacy Perspective

Theories on Metastasis: Innovative Thinking An Advocacy Perspective Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from

More information

Diagnostics guidance Published: 25 September 2013 nice.org.uk/guidance/dg10. NICE All rights reserved.

Diagnostics guidance Published: 25 September 2013 nice.org.uk/guidance/dg10. NICE All rights reserved. Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostratat Diagnostics

More information

ENABLING MORE INFORMED TREATMENT DECISIONS. PROMOTING PERSONALIZED PATIENT CARE. Innovative SOLUTIONS for COMPREHENSIVE Urological Cancer Care

ENABLING MORE INFORMED TREATMENT DECISIONS. PROMOTING PERSONALIZED PATIENT CARE. Innovative SOLUTIONS for COMPREHENSIVE Urological Cancer Care ENABLING MORE INFORMED TREATMENT DECISIONS. PROMOTING PERSONALIZED PATIENT CARE. Innovative SOLUTIONS for COMPREHENSIVE Urological Cancer Care Deep urology expertise combined with unrivaled solutions through

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

Trastuzumab (Herceptin ) for patients with metastatic breast cancer

Trastuzumab (Herceptin ) for patients with metastatic breast cancer JULY 2007 Incorporates published evidence to November 2006 INFORMATION ABOUT Trastuzumab (Herceptin ) for patients with metastatic breast cancer This information has been developed to help you understand

More information

Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors

Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors Chromosomal analysis for prenatal samples, peripheral blood, bone marrow biopsy samples, various types of lymphomas, and solid tumors FISH (fluorescence in situ hybridization) assays and many probes that

More information

Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)

Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD

More information

Proportion of patients with invasive breast cancer in whom ER, PR and/or

Proportion of patients with invasive breast cancer in whom ER, PR and/or 1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment

More information

Breast Cancer. Measurability of Quality Performance Indicators Version 1.3

Breast Cancer. Measurability of Quality Performance Indicators Version 1.3 Breast Cancer Measurability of Quality Permance Indicators Version 1.3 To be read in conjunction with: Breast Cancer Quality Permance Indicators Breast Cancer Data Definitions v1.0 Breast Cancer QPI Measurability

More information

Detailed Pathology Methods for Using Residual Cancer Burden

Detailed Pathology Methods for Using Residual Cancer Burden Detailed Pathology Methods for Using Residual Cancer Burden Residual cancer burden (RCB) is estimated from routine pathologic sections of the primary breast tumor site and the regional lymph nodes after

More information

National Medical Policy

National Medical Policy National Medical Policy The Medical Policy Department is no longer maintaining the Herceptin Policy. Please refer to the HNPS Prior Authorization Criteria Database which can be found at http://hnps.healthnet.com/pac/

More information

HER2. Improved Quality and Efficiency FISH. HER2 IQFISH pharmdx

HER2. Improved Quality and Efficiency FISH. HER2 IQFISH pharmdx WHI T E PAP E R FISH HER2 IQFISH pharmdx HER2 IQFISH pharmdx HER2 IQFISH pharmdx Improved Quality and Efficiency Improved Quality and Efficiency Debra S. Cohen, BS, CG(ASCAP)CM & Sharon Alsobrook, CG(ASCP)CM,

More information

Biomarker Trends in Breast Cancer Research

Biomarker Trends in Breast Cancer Research WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that

More information

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital

Targeted therapies for Early Stage Breast Cancer. Cynthia Vakhariya D.O. Providence Hospital Targeted therapies for Early Stage Breast Cancer Cynthia Vakhariya D.O. Providence Hospital Case 55-year-old postmenopausal woman Routine screening mammogram 3 cm irreg mass in L breast Left breast ultrasound

More information

Breast Cancer. Measurability of Quality Performance Indicators Version 1.0: April 2012

Breast Cancer. Measurability of Quality Performance Indicators Version 1.0: April 2012 Breast Cancer Measurability of Quality Performance Indicators Version 1.0: April 2012 (to be read in conjunction with the Breast Cancer Clinical Quality Performance Indicators Engagement Document v1.0

More information

BREAST CANCER IN YOUNG AGE ( 40 YEARS): THE UNIVERSITY OF TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE

BREAST CANCER IN YOUNG AGE ( 40 YEARS): THE UNIVERSITY OF TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE BREAST CANCER IN YOUNG AGE ( 40 YEARS): THE UNIVERSITY OF TENNESSEE MEDICAL CENTER AT KNOXVILLE 10 YEAR EXPERIENCE Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center

More information

J Clin Oncol 24:3032-3038. 2006 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24:3032-3038. 2006 by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment

More information

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)

ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in

More information

EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES. Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry

EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES. Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry EVALUATION OF LYMPH NODES & PATHOLOGIC EXAMINATION FOR BREAST CASES Tonya Brandenburg, MHA, CTR Kentucky Cancer Registry OBJECTIVES Review different methods of evaluating lymph nodes for breast cancer

More information

San Antonio Breast Cancer Symposium

San Antonio Breast Cancer Symposium Tuesday, December 9, EDUCATION SESSIONS 2:00 p.m. 5:30 p.m. Management of metastatic HER2 positive disease: optimizing current therapies and an overview of new agents in development - Ballroom B Reconstruction

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.

Metastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months. TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with

More information

TNM staging and prognosis. Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania

TNM staging and prognosis. Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania TNM staging and prognosis Alexandru Eniu, MD, PhD Medical Oncologist Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca, Romania The Basics of TNM Staging Premises: Cancers of the same

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE

DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE DOMINICAN HOSPITAL QUALITY IMPROVEMENT STUDY BREAST CANCER CARE STUDY COORDINATOR: Jimmy Chung, MD 234 Surgical breast cancer patients admitted 2004-2008 Updated: 10/7/10 INTRODUCTION Breast cancer is

More information

Positività per HER-2 nei carcinomi subcentimetrici

Positività per HER-2 nei carcinomi subcentimetrici Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,

More information

Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH)

Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH) Resolving Equivocal HER2 Status in Breast Cancer by Automated and Quantitative RNA Chromogenic In Situ Hybridization (CISH) USCAP, Vancouver, Canada, March 2012 Zhen Wang 1, Son Bui 2, Hongwei Wang 2,

More information

How can we generate economic value from personalized medicine and big data analysis?

How can we generate economic value from personalized medicine and big data analysis? Estonian Health Innovation Forum 2015 Focus on Personalised Medicine How can we generate economic value from personalized medicine and big data analysis? Jonathan Knowles October 26, 2015 Tallinn, Viru

More information

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof

More information

BREAST CANCER PATHOLOGY

BREAST CANCER PATHOLOGY BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know

More information

BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN?

BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN? BREAST CANCER WHAT DO MY BIOPSY RESULTS MEAN? Contents: The type of breast cancer The grade of the tumour Hormone receptor status HER2 status Questions to ask your doctor A biopsy is a procedure which

More information

cure to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More

cure to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More A Patient s Guide to HER2-Positive Breast Cancer What Is HER2? Making the Diagnosis Treatment Strategies Side Effects of Therapy Tips From a Survivor And More cure C a n c e r U p d a t e s, R e s e a

More information

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT

LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of

More information

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects

More information

ESMO 2014 Summary Breast Cancer

ESMO 2014 Summary Breast Cancer ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax

More information

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based

More information

Big Data and Oncology Care Quality Improvement in the United States

Big Data and Oncology Care Quality Improvement in the United States Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation

More information

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety,

NCT Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, NCT02020291 Preliminary Report: Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Metastatic Breast, Colon or Prostate

More information

The Value of Patient Advocacy in Laboratory Research--Making an Impact on Metastatic Breast Cancer Through the Rapid Autopsy Program

The Value of Patient Advocacy in Laboratory Research--Making an Impact on Metastatic Breast Cancer Through the Rapid Autopsy Program The Value of Patient Advocacy in Laboratory Research--Making an Impact on Metastatic Breast Cancer Through the Rapid Autopsy Program Lillie Shockney, RN., BS., MAS Administrative Director, Johns Hopkins

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative

More information

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers

Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers Review For reprint orders, please contact reprints@future-drugs.com Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers Walter P Carney CONTENTS Monitoring of HER2/neu oncoproteins

More information

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

Symposium article. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data Annals of Oncology 12 (Suppl. I): S57-S62, 2001. 2001 Kluwer Academic Publishers. Primed in the Netherlands. Symposium article Trastuzumab combined with chemotherapy for the treatment of HER2-positive

More information

Standardisation of HER2 analysis in carcinoma: Breast Cancer Lessons learned, lessons forgotten:

Standardisation of HER2 analysis in carcinoma: Breast Cancer Lessons learned, lessons forgotten: 6/7/ Standardisation of HER analysis in carcinoma: Breast Cancer Lessons learned, lessons forgotten: Dr John. M.S. Bartlett, Director of Transformative Pathology OICR HER testing in breast cancer. The

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer.

Breast Cancer. The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Breast Cancer What Does the Pathology Report Say Normal Cells The Pathology report gives an outline on direction of treatment. It tells multiple stories to help us understand the patient s cancer. Non-Invasive

More information

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS 1st International Congress on Controversies in Personalized Oncology (CONPO) BARCELONA, SPAIN MARCH

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies

More information

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Educational Program. June 5-6, 2015 Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:

More information

Oncotype-DX gene expression profile and chemotherapy decision-making in patients with early stage breast cancer

Oncotype-DX gene expression profile and chemotherapy decision-making in patients with early stage breast cancer Irish Society of Medical Oncology Evidence-based Series #1 Oncotype-DX gene expression profile and chemotherapy decision-making in patients with early stage breast cancer C.M Kelly and Members of the Irish

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information